| DESCRIPTION |
is a predominant and potent PPARa receptor agonist currently in Phase-I clinical trails being conducted in Canada. This new chemical entity (NCE) transactivates PPARa in a dose-dependent fashion, and has low PPARg activation at therapeutically relevant doses to treat lipid disorders. Preclinical pharmacological data shows that orally administered DRF-10945 has more potent triglyceride lowering, HDL elevating and overall anti-hyperlipidemic effects when compared to the existing fibrates. The toxicological profile of DRF-10945 suggests acceptable safety when characterized in single and repeat dose studies as well as in sub-chronic administrations over 2-4 weeks.
|